{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-26-000044","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2026-07-28T11:04:40+00:00","discovered_at":"2026-07-28T11:05:00.308869+00:00","generated_at":"2026-07-28T11:05:05.209491+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Altimmune reports positive Phase 2 RECLAIM trial of pemvidutide in alcohol use disorder","bullets":["Primary endpoint met: reduction in heavy drinking days/week vs placebo (LS mean diff -1.45, p=0.0014).","64.4% of pemvidutide patients achieved 2-level reduction in WHO Risk Drinking Level vs 34.8% placebo (p=0.0049).","Zero heavy drinking days in 42.2% of pemvidutide patients vs 17.4% placebo (p=0.0066).","Placebo-adjusted body weight reduction of 9.1% at 24 weeks (p<0.0001); no plateauing observed.","Company plans to request End-of-Phase 2 meeting with FDA based on these results."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-26-000044","json":"https://secwatch.observer/filing/0001326190-26-000044.json","markdown":"https://secwatch.observer/filing/0001326190-26-000044.md","text":"https://secwatch.observer/filing/0001326190-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/0001326190-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/alt-20260728x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T11:05:05.209491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}